Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Return on Capital Employed: 2014-2025

Historic Return on Capital Employed for Theravance Biopharma (TBPH) over the last 12 years, with Sep 2025 value amounting to -0.09%.

  • Theravance Biopharma's Return on Capital Employed rose 5.00% to -0.09% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.09%, marking a year-over-year increase of 5.00%. This contributed to the annual value of -0.14% for FY2024, which is 2.00% down from last year.
  • Theravance Biopharma's Return on Capital Employed amounted to -0.09% in Q3 2025, which was up 24.02% from -0.11% recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Return on Capital Employed ranged from a high of -0.09% in Q3 2025 and a low of -0.92% during Q1 2021.
  • Over the past 3 years, Theravance Biopharma's median Return on Capital Employed value was -0.14% (recorded in 2023), while the average stood at -0.13%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first crashed by 31bps in 2021, then soared by 64bps in 2022.
  • Quarterly analysis of 5 years shows Theravance Biopharma's Return on Capital Employed stood at -0.78% in 2021, then soared by 64bps to -0.14% in 2022, then declined by 1bps to -0.15% in 2023, then remained steady at -0.15% in 2024, then increased by 5bps to -0.09% in 2025.
  • Its Return on Capital Employed was -0.09% in Q3 2025, compared to -0.11% in Q2 2025 and -0.16% in Q1 2025.